Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Cash (2022 - 2025)

Historic Change in Cash for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.4 million.

  • Phathom Pharmaceuticals' Change in Cash fell 12466.29% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.5 million, marking a year-over-year decrease of 26488.74%. This contributed to the annual value of -$84.1 million for FY2024, which is 13684.04% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Change in Cash stood at -$14.4 million for Q3 2025, which was down 12466.29% from -$62.7 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Change in Cash high stood at $167.7 million for Q4 2023, and its period low was -$84.9 million during Q1 2025.
  • Its 4-year average for Change in Cash is -$3.0 million, with a median of -$32.8 million in 2023.
  • Examining YoY changes over the last 5 years, Phathom Pharmaceuticals' Change in Cash showed a top increase of 50460.52% in 2023 and a maximum decrease of 21116.16% in 2023.
  • Phathom Pharmaceuticals' Change in Cash (Quarter) stood at -$41.5 million in 2022, then surged by 504.61% to $167.7 million in 2023, then crashed by 122.31% to -$37.4 million in 2024, then surged by 61.48% to -$14.4 million in 2025.
  • Its Change in Cash stands at -$14.4 million for Q3 2025, versus -$62.7 million for Q2 2025 and -$84.9 million for Q1 2025.